Naturally occurring short splice variant of CYLD positively regulates dendritic cell function

Blood

Volumn 113, Issue 23, 2009, Pages 5891-5895

  Srokowski, Cathy Cecilia ^a   Masri, Joumana ^a   Hövelmeyer, Nadine ^a   Krembel, Anna Katharina ^a   Tertilt, Christine ^a   Strand, Dennis ^a   Mahnke, Karsten ^b   Massoumi, Ramin ^c   Waisman, Ari ^a   Schild, Hansjörg ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 3; PROTEIN P50; SYNAPTOTAGMIN I; CYLD PROTEIN, MOUSE; CYSTEINE PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYLD GENE; DENDRITIC CELL; GENE OVEREXPRESSION; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IMMUNOREGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UBIQUITINATION; ALTERNATIVE RNA SPLICING; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; METABOLISM; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ALTERNATIVE SPLICING; ANIMALS; CYSTEINE ENDOPEPTIDASES; DENDRITIC CELLS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 67651091771     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-08-175489     Document Type: Article

References (22)

1. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet. 2000;25:160-165. (Pubitemid 30394985)
2. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003;424:793-796. (Pubitemid 37021710)
3. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature. 2003;424:797-801. (Pubitemid 37021711)
4. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 2003;424: 801-805. (Pubitemid 37021712)
5. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R. Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell. 2006;125:665-677.
6. Hovelmeyer N, Wunderlich FT, Massoumi R, et al. Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. J Exp Med. 2007;204:2615-2627. (Pubitemid 350044787)
7. Zhang M, Wu X, Lee AJ, et al. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J Biol Chem. 2008;283:18621-18626.
8. Lim JH, Stirling B, Derry J, et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity. 2007;27:349-360. (Pubitemid 47284927)
9. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity. 2002;16: 257-270. (Pubitemid 34211965)
10. Warger T, Osterloh P, Rechtsteiner G, et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood. 2006;108:544-550. (Pubitemid 44061354)
11. Rechtsteiner G, Warger T, Hofmann M, Rammensee HG, Schild H, Radsak MP. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. Eur J Immunol. 2006;36:2613-2623. (Pubitemid 44608445)
12. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76:17-27. (Pubitemid 24035278)
13. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196:1627-1638. (Pubitemid 36026474)
14. Weih F, Carrasco D, Bravo R. Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen. Oncogene. 1994;9:3289-3297. (Pubitemid 24338457)
15. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 1989;17:6419.
16. Suhasini M, Reddy CD, Reddy EP, DiDonato JA, Pilz RB. cAMP-induced NF-kappaB (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation. Oncogene. 1997;15: 1859-1870. (Pubitemid 27478629)
17. Stassen M, Klein M, Becker M, et al. p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1. Mol Immunol. 2007;44:926-933. (Pubitemid 44415002)
18. Bopp T, Palmetshofer A, Serfling E, et al. NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells. J Exp Med. 2005;201:181-187. (Pubitemid 40189426)
19. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers. Genes Dev. 1993;7:1354-1363. (Pubitemid 23210884)
20. Nolan GP, Fujita T, Bhatia K, et al. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NFkappa B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol. 1993;13:3557-3566. (Pubitemid 23157293)
21. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405-455.
22. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683. (Pubitemid 26130197)